CSL (ASX:CSL) - Stock Price, News & Analysis

CSL Stock Overview

CSL fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 15.24% per year

Risk Analysis

No risks detected for CSL from our risk checks.

My Notes

New

Notes are coming soon

CSL Limited Competitors

Gilead Sciences

NasdaqGS:GILD

US$105.0b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$79.3b

Amgen

NasdaqGS:AMGN

US$135.3b

Vertex Pharmaceuticals

NasdaqGS:VRTX

US$82.5b

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share Price	AU$293.00
52 Week High	AU$304.70
52 Week Low	AU$240.10
Beta	0.18
1 Month Change	1.82%
3 Month Change	3.44%
1 Year Change	12.54%
3 Year Change	-5.91%
5 Year Change	100.08%
Change since IPO	36,525.37%

Recent updates

We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation

Oct 05

Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

Sep 02

CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate

Jul 22

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

Jul 01

Do CSL's (ASX:CSL) Earnings Warrant Your Attention?

May 20

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Mar 29

Is Weakness In CSL Limited (ASX:CSL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 08

A Look At The Fair Value Of CSL Limited (ASX:CSL)

Feb 19

Results: CSL Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 19

Here's Why I Think CSL (ASX:CSL) Might Deserve Your Attention Today

Feb 01

Announcing: CSL (ASX:CSL) Stock Increased An Energizing 152% In The Last Five Years

Jan 14

Our Take On CSL's (ASX:CSL) CEO Salary

Dec 24

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Dec 06

Is Weakness In CSL Limited (ASX:CSL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Jul 27

Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today?

Jul 06

Shareholder Returns

	CSL	AU Biotechs	AU Market
7D	-1.8%	-1.4%	0.6%
1Y	12.5%	11.8%	3.5%

Return vs Industry: CSL matched the Australian Biotechs industry which returned 11.8% over the past year.

Return vs Market: CSL exceeded the Australian Market which returned 3.5% over the past year.

Price Volatility

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.3%
Biotechs Industry Average Movement	9.1%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	15.7%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: CSL is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: CSL's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1916	30,000	Paul Perreault	https://www.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSL fundamental statistics
Market Cap	AU$142.11b
Earnings (TTM)	AU$3.17b
Revenue (TTM)	AU$14.86b

44.5x

P/E Ratio

9.5x

P/S Ratio

Is CSL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CSL income statement (TTM)
Revenue	US$10.56b
Cost of Revenue	US$4.83b
Gross Profit	US$5.73b
Other Expenses	US$3.48b
Earnings	US$2.25b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Feb 14, 2023

Earnings per share (EPS)	4.68
Gross Margin	54.27%
Net Profit Margin	21.35%
Debt/Equity Ratio	56.7%

How did CSL perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

46%

Payout Ratio

CSL Stock Overview

Rewards

Risk Analysis

CSL Limited Competitors

NasdaqGS:GILD

US$105.0b

NasdaqGS:REGN

US$79.3b

NasdaqGS:AMGN

US$135.3b

NasdaqGS:VRTX

US$82.5b

Price History & Performance

Recent News & Updates

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Recent updates

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Chairman exercised options to buy AU$74k worth of stock.

Independent Non-Executive Director recently bought AU$54k worth of stock

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

First half 2022 earnings: EPS and revenues exceed analyst expectations

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

MD, CEO & Executive Director recently sold AU$4.4m worth of stock

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation

MD, CEO & Executive Director recently sold AU$4.8m worth of stock

Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

High number of new directors

Upcoming dividend of US$1.18 per share

Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020)

CSL Limited Provides Financial Guidance for Fiscal 2022

CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

Independent Non-Executive Director Shah Hussain has left the company

Do CSL's (ASX:CSL) Earnings Warrant Your Attention?

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

Is Weakness In CSL Limited (ASX:CSL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Independent Non-Executive Chairman recently bought AU$82k worth of stock

New 90-day low: AU$263

First half 2021 earnings released: EPS US$3.98 (vs US$2.75 in 1H 2020)

Revenue and earnings beat expectations

A Look At The Fair Value Of CSL Limited (ASX:CSL)

Results: CSL Limited Exceeded Expectations And The Consensus Has Updated Its Estimates